Papers by Mona Kinkhabwala
Journal of Cardiac Failure, Dec 31, 2023
Expert Review of Cardiovascular Therapy, Feb 1, 2013
Blood, Nov 15, 2013
in Ca 2ϩ -handling proteins are thought to underlie the deranged Ca 2ϩ transients that contribute... more in Ca 2ϩ -handling proteins are thought to underlie the deranged Ca 2ϩ transients that contribute to deterioration of cardiac function in congestive heart failure (CHF). Clinical trials in CHF patients have shown that treatment with -adrenergic receptor antagonists (B) improves cardiac performance. The present study determined whether the abundance of Ca 2ϩ -handling proteins is different in failing hearts from patients treated or untreated with B. Methods and Results-Ca 2ϩ regulatory protein abundance was compared in LV myocardium of 10 nonfailing hearts (NF group) and 44 failing hearts (CHF group) removed at transplantation. Analysis was performed in B-treated (B-CHF) and non-B treated (non-B-CHF) patients and in 4 subgroups: ischemic cardiomyopathy (ICM, nϭ10), nonischemic dilated cardiomyopathy (DCM, nϭ10), ICM with B therapy (B-ICM, nϭ12), and DCM with B therapy (B-DCM, nϭ12). Sarcoplasmic reticulum Ca 2ϩ ATPase, phospholamban, and Na ϩ -Ca 2ϩ exchanger protein abundance were determined by use of Western blot analysis. Ca 2ϩ transients were measured with fluo-3. Sarcoplasmic reticulum Ca 2ϩ ATPase was significantly less abundant whereas phospholamban and Na ϩ -Ca 2ϩ exchanger were not significantly altered in non-B-CHF versus NF. Sarcoplasmic reticulum Ca 2ϩ ATPase in the B-ICM and B-DCM was greater than in non-B-CHF and were not different than in NF. Ca 2ϩ transients in non-B-CHF myocytes had significantly smaller peaks and were prolonged versus NF myocytes. Ca 2ϩ transients from B-CHF myocytes had shorter durations than in B-CHF myocytes. Conclusions-B treatment in CHF patients can normalize the abundance of myocyte Ca 2ϩ regulatory proteins and improve Ca 2ϩ -handling. (Circulation.
Journal of Nuclear Cardiology
Journal of the American College of Cardiology
The Journal of Nuclear Medicine, 2015
JACC: Cardiovascular Imaging, 2021
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in Engli... more Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Journal of the American College of Cardiology, 2015
Background: F-18Fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used for qua... more Background: F-18Fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used for qualitatively diagnosing vasculitis. However, there is no standardized method for quantification of vascular inflammation. We tested the reproducibility of FDG-PET in measuring aortic inflammation in patients with rheumatoid arthritis (RA). RA is a systemic inflammatory condition associated with increased cardiovascular risk. methods: We studied 10 non-diabetic RA patients (mean age 52.1 + 10.6 years, 80% female) who underwent FDG-PET imaging of the ascending aorta. All patients were on no carbohydrate diet for 24 hours and were imaged 90 minutes after FDG injection. The area of interest was defined as the region of the aorta beginning 1 cm above the origin of the left main coronary artery and ending at the aortic arch in transaxial view. Inflammation was measured as the mean of the maximal target-to-background ratio (meanTBRmax), defined as the ratio of the mean of the maximal standard uptake values (SUV) in the ascending aorta (meanSUVmax) and mean of the maximal SUV in either the brachiocephalic vein or superior vena cava, whichever was the lesser value (bckgrnd). Regions of interest in the aorta were hand-drawn and included the vessel wall. Regions of interest in the brachiocephalic vein or superior vena cava were a minimum of 3 pixels in size and 0.3 cm2 in area and measured the blood pool background. Each study was read by 3 experienced readers using MedView Software (MedImage, Ann Arbor, MI). results: Each meanTBRmax was derived from, on average, 10 independent transaxial slice measurements of the ascending aorta. Bckgrnd was derived from the average of 6 transaxial measurements. Interobserver correlation coefficients of reliability were calculated using ANOVA for meanSUVmax, bckgrnd and meanTBRmax, and were 0.997, 0.992 and 0.922, respectively. conclusion: We have developed a method for measuring inflammation in the ascending aorta for RA patients that is facile and highly reproducible. Using this method, FDG-PET can be used to monitor vascular inflammation in this population of patients.
Journal of Nuclear Cardiology, Oct 28, 2020
Journal of Nuclear Cardiology
The Journal of Nuclear Medicine, 2015
Journal of the American College of Cardiology, 2021
BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and ... more BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified. OBJECTIVES The study sought to assess COVID-19's impact on global cardiovascular diagnostic procedural volumes and safety practices. METHODS The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained. RESULTS Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoracic echocardiography decreased by 59%, transesophageal echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p < 0.001 for each procedure). In multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower-middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and telehealth. CONCLUSIONS COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19-related changes in care delivery is warranted.
Journal of Nuclear Cardiology
JACC: Cardiovascular Imaging
JACC: Cardiovascular Imaging
JACC: Cardiovascular Imaging
Journal of Nuclear Cardiology, 2016
Journal of Nuclear Cardiology, 2016
Uploads
Papers by Mona Kinkhabwala